Relacorilant: FDA Approved GR Antagonist for Ovarian Cancer
Review the FDA approval of relacorilant (Lifyorli) for platinum-resistant ovarian cancer. Learn its clinical efficacy and mechanism as a GR antagonist.
Back to Articles
Articles tagged with “ovarian-cancer”